Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance.
Colitis, ulcerative
Golimumab
Product surveillance, postmarketing
Safety and effectiveness
Journal
Intestinal research
ISSN: 1598-9100
Titre abrégé: Intest Res
Pays: Korea (South)
ID NLM: 101572802
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
23
02
2021
accepted:
07
06
2021
pubmed:
3
8
2021
medline:
3
8
2021
entrez:
2
8
2021
Statut:
ppublish
Résumé
Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness in patients with UC in Japan. We present an interim report of the ongoing PMS. Patients received 200 mg of subcutaneous GLM at week 0, 100 mg at week 2, and 100 mg 4 weekly thereafter. The safety analysis set included 392 patients with UC, and the effectiveness analysis set 387 patients. Safety and effectiveness were assessed at week 6. Adverse drug reactions (ADRs) were reported in 8.2% (32/392) and serious ADRs in 4.6% (18/392). The most frequent ADRs were infection and infestation (3.3%), with herpes zoster being the most common. ADRs were significantly higher in patients with concomitant corticosteroid use (odds ratio [OR], 3.45; 95% confidence interval [CI], 1.40-9.68). No significant difference in ADR incidence was observed between patients aged ≥65 and <65 years (OR, 1.23; 95% CI, 0.35-3.47). Six-week effectiveness of GLM was confirmed by a decrease in the partial Mayo score (-2.3; 95% CI, -2.6 to -2.1) and C-reactive protein levels (-0.64; 95% CI, -0.92 to -0.36), including in the biologics-experienced population. The safety and effectiveness of GLM at week 6 in a real-world setting were demonstrated in patients with UC in Japan. ADR patterns were consistent with previous reports with no new safety signals. Concomitant corticosteroid use may be associated with increased ADR incidence. The final results of the ongoing PMS are necessary for further evaluation.
Sections du résumé
BACKGROUND/AIMS
OBJECTIVE
Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness in patients with UC in Japan. We present an interim report of the ongoing PMS.
METHODS
METHODS
Patients received 200 mg of subcutaneous GLM at week 0, 100 mg at week 2, and 100 mg 4 weekly thereafter. The safety analysis set included 392 patients with UC, and the effectiveness analysis set 387 patients. Safety and effectiveness were assessed at week 6.
RESULTS
RESULTS
Adverse drug reactions (ADRs) were reported in 8.2% (32/392) and serious ADRs in 4.6% (18/392). The most frequent ADRs were infection and infestation (3.3%), with herpes zoster being the most common. ADRs were significantly higher in patients with concomitant corticosteroid use (odds ratio [OR], 3.45; 95% confidence interval [CI], 1.40-9.68). No significant difference in ADR incidence was observed between patients aged ≥65 and <65 years (OR, 1.23; 95% CI, 0.35-3.47). Six-week effectiveness of GLM was confirmed by a decrease in the partial Mayo score (-2.3; 95% CI, -2.6 to -2.1) and C-reactive protein levels (-0.64; 95% CI, -0.92 to -0.36), including in the biologics-experienced population.
CONCLUSIONS
CONCLUSIONS
The safety and effectiveness of GLM at week 6 in a real-world setting were demonstrated in patients with UC in Japan. ADR patterns were consistent with previous reports with no new safety signals. Concomitant corticosteroid use may be associated with increased ADR incidence. The final results of the ongoing PMS are necessary for further evaluation.
Identifiants
pubmed: 34333910
pii: ir.2021.00032
doi: 10.5217/ir.2021.00032
pmc: PMC9344245
doi:
Types de publication
Journal Article
Langues
eng
Pagination
329-341Subventions
Organisme : Janssen Pharmaceuticals
Organisme : Mitsubishi Tanabe Pharma Corporation
Références
Clin J Gastroenterol. 2019 Feb;12(1):1-9
pubmed: 30206776
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
Gastroenterology. 2020 Apr;158(5):1465-1496.e17
pubmed: 31945351
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
Gastroenterology. 2008 Apr;134(4):929-36
pubmed: 18294633
Aliment Pharmacol Ther. 2013 Feb;37(4):420-9
pubmed: 23240738
Aliment Pharmacol Ther. 2015 Apr;41(7):613-23
pubmed: 25652884
Frontline Gastroenterol. 2018 Jul;9(3):221-231
pubmed: 30047549
Nat Rev Dis Primers. 2020 Sep 10;6(1):74
pubmed: 32913180
N Engl J Med. 2019 Sep 26;381(13):1201-1214
pubmed: 31553833
Gastroenterology. 2020 Apr;158(5):1464
pubmed: 32169295
Clin Gastroenterol Hepatol. 2011 Jan;9(1):30-5
pubmed: 20951835
Curr Med Res Opin. 2019 Nov;35(11):1911-1923
pubmed: 31192706
MAbs. 2010 Jul-Aug;2(4):428-39
pubmed: 20519961
BMJ Open Gastroenterol. 2018 Jul 07;5(1):e000212
pubmed: 30002864
Gastroenterology. 2014 Jan;146(1):85-95; quiz e14-5
pubmed: 23735746
Dig Dis Sci. 2020 Jun;65(6):1767-1776
pubmed: 31722059
BMC Gastroenterol. 2020 May 12;20(1):147
pubmed: 32398011
Patient Prefer Adherence. 2018 Jul 06;12:1193-1202
pubmed: 30013330
World J Gastroenterol. 2016 Nov 14;22(42):9300-9313
pubmed: 27895418
J Gastroenterol Hepatol. 2018 Nov;33(11):1839-1843
pubmed: 29669163
J Gastroenterol. 2017 Oct;52(10):1101-1111
pubmed: 28324167
Gastroenterology. 2014 Jan;146(1):96-109.e1
pubmed: 23770005
Dig Liver Dis. 2019 Mar;51(3):327-334
pubmed: 30555013
Inflamm Bowel Dis. 2018 Sep 15;24(10):2258-2265
pubmed: 29850873
J Gastrointestin Liver Dis. 2017 Sep;26(3):239-244
pubmed: 28922435
N Engl J Med. 2017 May 4;376(18):1723-1736
pubmed: 28467869
Inflamm Bowel Dis. 2017 Jun;23(6):882-893
pubmed: 28375885
Inflamm Bowel Dis. 2017 Aug;23(8):1394-1402
pubmed: 28671873
Arthritis Rheum. 2008 Nov;58(11):3402-12
pubmed: 18975305
J Gastroenterol. 2019 Jul;54(7):571-586
pubmed: 31025187
Cytokine. 2018 Jan;101:56-63
pubmed: 27567553
J Dig Dis. 2018 Aug;19(8):468-474
pubmed: 30039533
Br Med J. 1955 Oct 29;2(4947):1041-8
pubmed: 13260656
J Crohns Colitis. 2018 Apr 27;12(5):600-609
pubmed: 29718244
Arthritis Rheum. 2009 Apr;60(4):976-86
pubmed: 19333944
Clin Gastroenterol Hepatol. 2020 Jan;18(1):69-81.e3
pubmed: 30876964
Clin Rheumatol. 2015 Dec;34(12):2119-26
pubmed: 25956956
Scand J Gastroenterol. 2015 Aug;50(8):1018-24
pubmed: 25861832
Arthritis Rheum. 2006 Jun 15;55(3):420-6
pubmed: 16739208
Ann Rheum Dis. 2018 Jan;77(1):21-29
pubmed: 28507219
Immunity. 2019 Apr 16;50(4):992-1006
pubmed: 30995511
Dig Dis Sci. 2017 Feb;62(2):481-490
pubmed: 27995400
J Gastrointestin Liver Dis. 2020 Jun 03;29(2):167-173
pubmed: 32530983
J Gastroenterol. 2018 Mar;53(3):305-353
pubmed: 29429045
J Gastroenterol. 2017 May;52(5):555-567
pubmed: 27470433
Inflamm Bowel Dis. 2004 Jul;10(4):436-7
pubmed: 15475754
Inflamm Bowel Dis. 2008 Dec;14(12):1660-6
pubmed: 18623174
Arthritis Rheum. 2008 Apr;58(4):964-75
pubmed: 18383539